- Boston Scientific enhances its market position with FDA approval for Bolt Medical's IVL system.
- Analysts forecast a potential 16.43% upside for BSX, with a target price of $117.36.
- Despite a strong "Outperform" rating, GuruFocus estimates suggest a potential downside based on GF Value.
Boston Scientific (BSX, Financial) has achieved a significant milestone by securing FDA approval for the intravascular lithotripsy (IVL) system developed by Bolt Medical. This is a notable advancement following Boston Scientific's strategic acquisition of Bolt, initially valued at $664 million. The innovative IVL system uses sound waves to break down calcified blockages within vessels and has successfully passed critical safety and efficacy trials. With this FDA approval, Boston Scientific is set to reinforce its leadership in the percutaneous transluminal angioplasty market.
Wall Street Analysts Forecast
According to the analysis of 28 analysts, the one-year price targets for Boston Scientific Corp (BSX, Financial) present an average target of $117.36, with projections ranging from a high of $130.00 to a low of $84.11. This average target suggests a potential upside of 16.43% from the current trading price of $100.80. For a deeper dive into these projections, visit the Boston Scientific Corp (BSX) Forecast page.
Furthermore, the consensus recommendation from 33 brokerage firms indicates an average brokerage rating of 1.8 for Boston Scientific Corp (BSX, Financial), categorizing it as "Outperform." The rating scale ranges from 1, representing a Strong Buy, to 5, indicating a Sell.
GuruFocus's GF Value Estimation
Based on GuruFocus's proprietary metrics, the estimated GF Value for Boston Scientific Corp (BSX, Financial) in one year is calculated at $76.94. This suggests a potential downside of 23.67% from the current price of $100.80. The GF Value represents GuruFocus's estimation of the fair value at which the stock should be traded, derived from historical trading multiples, past business growth, and future business performance projections. For additional insights and data, refer to the Boston Scientific Corp (BSX) Summary page.
This blend of positive analyst sentiment and cautious valuation metrics highlights the importance of a balanced investment strategy, offering both opportunities and challenges for discerning investors.
